Strategic Alliances HospitalHealth collaboration on ADS032 provides external validation and potential co-development or licensing opportunities for a dual inflammasome inhibitor targeting NLRP1 and NLRP3, creating trigger points for BD outreach to inflammatory disease programs.

Diversified Asset Portfolio A dual asset strategy with ADS032 and ADS024 opens multiple partnering paths, including small molecule and live biotherapeutic collaborations, co-development deals, and out-licensing across inflammatory indications and potential respiratory applications.

Funding Backbone With roughly $60M in funding and modest current revenue, Adiso has runway to pursue partnerships and milestone-driven deals, leveraging external capital to advance clinical programs while minimizing internal burn.

Clinical Momentum Existing Phase 1 programs in ulcerative colitis and Clostridioides difficile infection, plus a Phase 2 UC program, create near-term milestones attractive to potential pharma partners seeking de-risked collaboration opportunities.

Strategic Signals Board expansion and investor network, including a new director and Morningside Ventures backing, broaden deal-sourcing opportunities and strategic access to potential co-development and licensing partners.